行为减重与二甲双胍对癌症幸存者IGF-1的影响:随机试验
该随机三臂试验纳入121名超重或肥胖癌症幸存者,比较自主减重、教练指导减重与二甲双胍治疗。6个月时二甲双胍组IGF-1及IGF-1:IGFBP3摩尔比较自主减重组显著下降,但12个月时组间无差异。结论提示二甲双胍对肥胖癌症幸存者IGF-1的降低作用短暂且随时间减弱。
要点
- 二甲双胍治疗3个月时IGF-1较自主减重组显著下降(平均差值-5.50 ng/mL,P=0.02)。
- 肥胖亚组6个月时IGF-1下降更明显(平均差值-7.2 ng/mL,95%CI -13.3至-1.1)。
- 教练指导减重组与自主减重组在IGF-1变化上无显著差异。
核心结论
- 在肥胖癌症幸存者中,二甲双胍可能短期降低IGF-1,但效果随时间减弱。
研究设计与样本
- 随机、三平行臂对照临床试验,纳入121名超重或肥胖癌症幸存者,79%为女性,46%为非裔美国人,平均年龄60岁。
主要发现
- 6个月体重变化:自主减重组-1.0%(P=0.07),教练指导组-4.2%(P<0.0001),二甲双胍组-2.8%(P<0.0001)。
- 3个月时二甲双胍组较自主减重组IGF-1平均变化差值为-5.50 ng/mL(P=0.02),IGF1:IGFBP3摩尔比平均变化差值为-0.0119(P=0.011)。
- 肥胖参与者6个月时IGF-1平均变化差值-7.2 ng/mL(95%CI -13.3至-1.1),超重参与者无此差异(交互P=0.045)。
- 教练指导组与自主减重组各结局变化无显著差异,12个月时各组结局无差异。
临床怎么用
- 对肥胖癌症幸存者,二甲双胍可考虑用于短期降低IGF-1,但需知晓效果可能不持久。
- 行为减重(教练指导或自主)在本研究中未显著改变IGF-1,不应以降低IGF-1为主要目的。
局限性
- 样本量121例,随访12个月,长期效果未知。
- 原文未报告部分亚组分析细节及依从性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Higher levels of insulin-like growth factor-1 (IGF-1) are associated with increased risk of cancers and higher mortality. Therapies that reduce IGF-1 have considerable appeal as means to prevent recurrence. DESIGN: Randomized, 3-parallel-arm controlled clinical trial. INTERVENTIONS AND OUTCOMES: Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment. Main outcomes were changes in IGF-1 and IGF-1:IGFBP3 molar ratio at 6 months. The trial duration was 12 months. RESULTS: Of the 121 randomized participants, 79% were women, 46% were African Americans, and the mean age was 60 years. At baseline, the average body mass index was 35 kg/m2; mean IGF-1 was 72.9 (SD, 21.7) ng/mL; and mean IGF1:IGFBP3 molar ratio was 0.17 (SD, 0.05). At 6 months, weight changes were -1.0% (P = 0.07), -4.2% (P < 0.0001), and -2.8% (P < 0.0001) in self-directed, coach-directed, and metformin groups, respectively. Compared with the self-directed group, participants in metformin had significant decreases on IGF-1 (mean difference in change: -5.50 ng/mL, P = 0.02) and IGF1:IGFBP3 molar ratio (mean difference in change: -0.0119, P = 0.011) at 3 months. The significant decrease of IGF-1 remained in participants with obesity at 6 months (mean difference in change: -7.2 ng/mL; 95% CI: -13.3 to -1.1), but not in participants with overweight (P for interaction = 0.045). There were no significant differences in changes between the coach-directed and self-directed groups. There were no differences in outcomes at 12 months. CONCLUSIONS: In cancer survivors with obesity, metformin may have a short-term effect on IGF-1 reduction that wanes over time.
引用
- Yeh HC, Maruthur NM, Wang NY, et al. Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. J Clin Endocrinol Metab. 2021. PMID: 33884414. doi:10.1210/clinem/dgab266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。